News | June 08, 2009

Study Finds 3D Echo is a Stronger Outcome Predictor Than 2D

June 9, 2009 – Physicians can better predict potentially life-threatening cardiac events with real-time, three-dimensional echocardiography technology, according to a study released at the 20th Annual Scientific Sessions of the American Society of Echocardiography (ASE) in Washington, D.C.

The study concluded that 3D measurements could help guide management decisions on how to best treat the patient and better predict the patient’s chance of survival.

Left ventricular end systolic volume measured by 2D echocardiography is an important correlate of survival. Researchers sought to determine whether 3D echo was more predictive of outcome than 2D echo. The study included 535 patients referred for left ventricle assessment. Patients were assessed with 2D and 3D echocardiography.

Over four to five years, cardiac admission, incident heart failure, atrial fibrillation and all-cause mortality information was obtained in 461 of 504 patients with images suitable for measurement. The results showed 48 cardiac events (10 percent) including 34 deaths. Larger left ventricular end-systolic volume and lower ejection fraction were associated with worse outcome.

The addition of 2D echo end-systolic volume increased the association of clinical variables—renal disease, left ventricular impairment and age – with outcome, but 3D echo end-systolic volume increased the strength of association. Similarly, the incremental value of 2D echo ejection fraction was exceeded by 3D echo ejection fraction.

The study was conducted by Carly Jenkins, Tony Stanton and Thomas H. Marwick at University of Queensland in Woolloongabba, Australia.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
Subscribe Now